1887

n Cardiovascular Journal of Africa - Bayer's Xarelto® is approved in South Africa across five additional indications - advertorial : drug trends in cardiology

USD

 

Abstract

Bayer HealthCare's oral anticoagulant Xarelto® 15 and 20 (rivaroxaban) has been approved by the Medicines Control Council of South Africa for use in five new indications, making it the only new oral anticoagulant approved in six indications across the world.

Loading

Article metrics loading...

/content/cardio1/25/2/EJC151891
2014-03-01
2016-12-05
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error